Kiniksa Pharmaceuticals Q3 ARCALYST revenue jumps 58%; raises guidance
KNSA•Kiniksa Pharmaceuticals said Q3 ARCALYST revenue rose 58% year over year to $286 million and net income more than doubled to $47.3 million. It raised 2026 ARCALYST revenue guidance to $1.045 billion-$1.050 billion.
1. Revenue and earnings
Kiniksa Pharmaceuticals reported Q3 ARCALYST revenue of $285.97 million, up 58% year over year. Net income rose to $47.35 million from $18.4 million a year earlier; earnings per share were $0.56.
2. Raised 2026 outlook
The company raised its 2026 ARCALYST net product revenue guidance to $1.045 billion-$1.050 billion. It expects research and development expenses of $160 million-$170 million and selling, general and administrative expenses of $270 million-$280 million, and expects to remain cash flow positive annually under its current operating plan.
3. Adoption and costs
Kiniksa said commercial execution drove gains in patient and physician adoption of ARCALYST for recurrent pericarditis. It attributed higher operating expenses mainly to increased ARCALYST sales and commercialization investment, and increased research and development expenses mainly to higher KPL-387 clinical activity.
